# Efforts Focused on Fatty Liver over Two Years (2023-2025): A Thematic Literature Review

## TL;DR

This paper reviews recent scientific and technological advances in the study and management of metabolic dysfunction-associated steatotic liver disease (MASLD) from 2023 to 2025.

## Contribution

The study provides a scientometric analysis of MASLD research, highlighting emerging trends in AI, mobile apps, and therapies.

## Key findings

- Major scientific meetings and highly cited publications have advanced MASLD research.
- FDA-approved therapies and digital tools like AI and mobile apps are emerging in MASLD management.
- Public perceptions and search frameworks show growing interest in MASLD-related topics.

## Abstract

Nonalcoholic fatty liver disease, recently recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), is a key factor in the development of chronic liver disease and the progression of liver fibrosis. It plays a significant role in increasing the risk of cirrhosis and hepatocellular carcinoma. Given the rapid developments in this field, keeping information up-to-date is essential to prevent misconceptions and ineffective decision-making. This study employs a scientometric approach to review scientific literature and analyze recent findings, offering a comprehensive overview of the current state of research in this field.

In this approach, we explored data related to publication metrics, public perceptions, scientific conference, mobile apps, AI tools, and new medications. This was done using a set of keywords, including "Non-alcoholic fatty liver disease," "Metabolic dysfunction-associated steatotic liver disease," "Mobile application," and "Artificial intelligence."

This research highlights significant scientific advances in the field of MASLD, including major scientific meetings, highly cited publications, and the latest FDA-approved therapies. In addition, it examines emerging digital tools and public search frameworks, providing a structured picture of recent developments. These findings provide a comprehensive view of the dynamic MASLD research landscape and emphasize the roles of AI, mobile apps, and emerging therapies in its management.